The pharmaceutical industry’s ability to evolve alongside innovations in technology and science increases with the incorporation of digital systems and redesigned data collectors. Pharma 4.0™ is a trending industry initiative that highlights the impact and benefit of digitalisation in pharma operations and production. Digitalisation of pharma manufacturing can propel the industry forward and facilitate technological, economical, and logistical advancement.
There are very different perspectives and drivers to Pharma 4.0™ for the different stakeholders:
The 2019 ISPE Europe Pharma 4.0™ Conference is an interactive forum where top business leaders and CEOs of the industry will discuss their strategic plans for the future of pharmaceutical engineering with the implementation of digitalisation.
The two-day event will answer questions like:
Unlike other huge events, you'll have the opportunity to connect directly with knowledgeable presenters representing leading organisations, including FDA, GSK, LifeBee, MHRA, Merck, Siemens UK, Werum IT Solutions, and more.
Register today for the 2019 ISPE Europe Pharma 4.0™ Conference to stay on track with the latest evolutions on the Pharma 4.0™ topic to successfully implement strategies for your company. Come early and take advantage of in-depth training on 18–19 November to take a deeper dive into three critical areas of pharma manufacturing.
Through the ISPE Foundation Professional Development Grant program, Silas Tamufor attended the 2023 ISPE Annual Meeting & Expo in October 2023. Tamufor is a PhD student and ISPE Boston Chapter member who began serving as the ISPE Boston Educational Programs Committee Chair in December 2023. He, along with 87 other students and recent graduates, attended the conference thanks to the...
To meet the biopharmaceutical industry’s duty to manufacture safe and effective therapies for patients, a robust quality system is fundamental to success. A quality system should link to quality culture and prioritize focusing on quality, led by management, that fosters sustainable compliance and consistent production of high-quality drugs. Strong quality culture attributes include a proactive...
Stability sampling and testing are key to ensuring that products maintain safety, identity, strength, purity, and quality throughout their claimed shelf life. It is also a regulatory requirement per ICH Q5. However, storing product samples in different environmental conditions, testing those samples for three to five years (or more) after initial manufacture, and properly analyzing and...